Skip to main content
. 2019 Dec 2;9:18021. doi: 10.1038/s41598-019-54226-7

Figure 4.

Figure 4

Schematic overview of three commercially available anti-VEGF biologics. Ranibizumab (a) is composed of the affinity maturated Fab of bevacizumab, (b) bevacizumab is a full-length IgG1 antibody and (c) aflibercept is composed of domains from VEGFR1 and 2 fused to an IgG1 Fc-region. The figure was created with BioRender software.